PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
Metrics to compare | PCIB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPCIBPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.0x | 0.0x | −0.5x | |
PEG Ratio | −0.15 | 0.00 | 0.00 | |
Price / Book | 2.1x | 0.0x | 2.6x | |
Price / LTM Sales | 7.2x | 0.0x | 2.9x | |
Upside (Analyst Target) | - | 0.0% | 66.0% | |
Fair Value Upside | Unlock | 0.0% | 10.6% | Unlock |